Evidence map›Paper›PMID 27881463›Full record

ArticleCarcinogenesis2017

Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.

Naghma Khan, Farah Jajeh, Mohammad Imran Khan, Eiman Mukhtar, Sameh M Shabana, Hasan Mukhtar

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Use of cucurbitacins for lung cancer research and therapy.Cancer chemotherapy and pharmacology · 2021
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Naghma KhanDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
Farah JajehDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
Mohammad Imran KhanDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
Eiman MukhtarDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
Sameh M ShabanaDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
Hasan MukhtarDepartment of Dermatology, University of Wisconsin, Madison, WI 53706, USA and.
University of Wisconsin–Madison · US

Funding

Developing Fisetin for the Managment of Prostate CancerR01CA160867 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA160867
6 · The paper itself

Abstract

Many purified compounds from dietary sources have been investigated for their anticancer activities. The main issue with most agents is their effectiveness at high doses which generally could not be delivered to humans through dietary consumption. Here, we observed that cucurbitacin B, a tetracyclic triterpenoid present in pumpkins, gourds and squashes, exhibits antiproliferative effects on human non-small cell lung cancer (NSCLC) cells at nanomolar concentrations. Treatment with cucurbitacin B (0.2-0.6 μM; 24 h) was found to result in decrease in the viability of EGFR-wild type (A549 and H1792) and EGFR-mutant lung cancer cells (H1650 and H1975) and reduction in cell-colonies but had only minimal effect on normal human bronchial epithelial cells. Treatment with cucurbitacin B also caused inhibition of PI3K/mTOR and signal transducer and activator of transcription (STAT)-3 signaling along with simultaneous activation of AMPKα levels in both EGFR-wild type and EGFR-mutant lung cancer cells. Cucurbitacin B caused specific increase in the protein and mRNA expression of sestrin-3 in EGFR-mutant lung cancer cells, but not in EGFR-wild type cells. Treatment with cucurbitacin B to sestrin-3 siRNA treated EGFR-mutant cells further amplified the decrease in cell-viability and caused more sustained G2-phase cell cycle arrest, suggesting that these effects are mediated partly through sestrin-3. We also found that sestrin-3 has a role in the induction of apoptosis by cucurbitacin B in both EGFR-wild type and EGFR-mutant lung cancer cells. These findings suggest novel mechanism by the modulation of sestrin-3 for the action of cucurbitacin B and suggest that it could be developed as an agent for therapy of NSCLC.

Indexed as

A549 CellsApoptosisCell Cycle CheckpointsCell ProliferationErbB ReceptorsGene Expression Regulation, NeoplasticHeat-Shock ProteinsHumansLung NeoplasmsMutationPhosphatidylinositol 3-KinasesSestrinsSignal TransductionTriterpenescucurbitacin BEGFR protein, humanErbB ReceptorsHeat-Shock ProteinsPhosphatidylinositol 3-KinasesSESN3 protein, humanSestrinsTriterpenes

Identifiers

PMID27881463
PMCPMC6075515
OpenAlexW2558097772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.